{"title":"纳曲酮治疗 OUD 的快速启动方案","authors":"Alison Knopf","doi":"10.1002/cpu30877","DOIUrl":null,"url":null,"abstract":"<p>Your idea of “rapid” may be different from that of the National Institute on Drug Abuse (NIDA), which funded a study showing that it is possible to start patients on injectable, extended-release naltrexone (trade name Vivitrol) within five to seven days after they stop opioid use — and called that “rapid initiation.” But it's all relative. The standard treatment method was within 10–15 days, according to NIDA. The new finding shortens that painful period.</p>","PeriodicalId":22496,"journal":{"name":"The Brown University Child & Adolescent Psychopharmacology Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rapid initiation protocol for naltrexone for OUD\",\"authors\":\"Alison Knopf\",\"doi\":\"10.1002/cpu30877\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Your idea of “rapid” may be different from that of the National Institute on Drug Abuse (NIDA), which funded a study showing that it is possible to start patients on injectable, extended-release naltrexone (trade name Vivitrol) within five to seven days after they stop opioid use — and called that “rapid initiation.” But it's all relative. The standard treatment method was within 10–15 days, according to NIDA. The new finding shortens that painful period.</p>\",\"PeriodicalId\":22496,\"journal\":{\"name\":\"The Brown University Child & Adolescent Psychopharmacology Update\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Child & Adolescent Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cpu30877\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Child & Adolescent Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpu30877","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Your idea of “rapid” may be different from that of the National Institute on Drug Abuse (NIDA), which funded a study showing that it is possible to start patients on injectable, extended-release naltrexone (trade name Vivitrol) within five to seven days after they stop opioid use — and called that “rapid initiation.” But it's all relative. The standard treatment method was within 10–15 days, according to NIDA. The new finding shortens that painful period.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
